Recent Updates
Recently added Catalysts

Abemaciclib

Phase 3

Non Small Cell Lung Cancer | Small molecule | Oncology |Eli Lilly and Company|Last Updated: Jul 17, 2026

Success Probability
Subscribe to view
Market & Valuation
Subscribe to view
Trial Design
RandomizedCONTROLLEDDMC
Total Trials2
Total Enrollment553
FDA Designations
No designations recorded
Clinical trial landscape

Abemaciclib · 51 trials · 110 indications

Phase 3 8Phase 2 26Phase 1 16Early Phase 1 1
NCT05288166A Study of Abemaciclib (LY2835219) With Abiraterone in Men With Prostate Cancer That Has Spread to Other Parts of the Body and is Expected to Respond to Hormonal Treatment (Metastatic Hormone-Sensitive Prostate Cancer)Prostatic Neoplasms
ACTIVE NOT_RECRUITING925 Analytics
NCT05169567Abemaciclib (LY2835219) Plus Fulvestrant Compared to Placebo Plus Fulvestrant in Previously Treated Breast CancerBreast Neoplasm
ACTIVE NOT_RECRUITING368 Analytics
NCT04967521SARC041: Study of Abemaciclib Versus Placebo in Patients with Advanced Dedifferentiated LiposarcomaAdvanced Dedifferentiated Liposarcoma
ACTIVE NOT_RECRUITING108 Analytics
NCT03155997Endocrine Therapy With or Without Abemaciclib (LY2835219) Following Surgery in Participants With Breast CancerBreast Cancer
ACTIVE NOT_RECRUITING5,637 Analytics
NCT02763566A Study of Abemaciclib (LY2835219) in Participants With Breast CancerBreast Cancer
ACTIVE NOT_RECRUITING463 Analytics
NCT02246621A Study of Nonsteroidal Aromatase Inhibitors Plus Abemaciclib (LY2835219) in Postmenopausal Women With Breast CancerBreast Cancer
ACTIVE NOT_RECRUITING493 Analytics
NCT02152631A Study of Abemaciclib (LY2835219) in Participants With Previously Treated KRAS Mutated Lung CancerNon Small Cell Lung Cancer
ACTIVE NOT_RECRUITING453 Analytics
NCT02107703A Study of Abemaciclib (LY2835219) Combined With Fulvestrant in Women With Hormone Receptor Positive HER2 Negative Breast CancerBreast Neoplasms
ACTIVE NOT_RECRUITING669 Analytics
PHASE3ACTIVE NOT_RECRUITING
A Study of Abemaciclib (LY2835219) With Abiraterone in Men With Prostate Cancer That Has Spread to Other Parts of the Body and is Expected to Respond to Hormonal Treatment (Metastatic Hormone-Sensitive Prostate Cancer)
Prostatic NeoplasmsUnlock trial analytics
PHASE3ACTIVE NOT_RECRUITING
Abemaciclib (LY2835219) Plus Fulvestrant Compared to Placebo Plus Fulvestrant in Previously Treated Breast Cancer
Breast NeoplasmUnlock trial analytics
PHASE3ACTIVE NOT_RECRUITING
SARC041: Study of Abemaciclib Versus Placebo in Patients with Advanced Dedifferentiated Liposarcoma
Advanced Dedifferentiated LiposarcomaUnlock trial analytics
PHASE3ACTIVE NOT_RECRUITING
Endocrine Therapy With or Without Abemaciclib (LY2835219) Following Surgery in Participants With Breast Cancer
Breast CancerUnlock trial analytics
PHASE3ACTIVE NOT_RECRUITING
A Study of Abemaciclib (LY2835219) in Participants With Breast Cancer
Breast CancerUnlock trial analytics
PHASE3ACTIVE NOT_RECRUITING
A Study of Nonsteroidal Aromatase Inhibitors Plus Abemaciclib (LY2835219) in Postmenopausal Women With Breast Cancer
Breast CancerUnlock trial analytics
PHASE3ACTIVE NOT_RECRUITING
A Study of Abemaciclib (LY2835219) in Participants With Previously Treated KRAS Mutated Lung Cancer
Non Small Cell Lung CancerUnlock trial analytics
PHASE3ACTIVE NOT_RECRUITING
A Study of Abemaciclib (LY2835219) Combined With Fulvestrant in Women With Hormone Receptor Positive HER2 Negative Breast Cancer
Breast NeoplasmsUnlock trial analytics
Study Endpoints
Primary Endpoints
Radiographic Progression-Free Survival (rPFS) Assessed by Investigator
From Date of Randomization to Radiographic Disease Progression or Death from Any Cause (up to 22 months)

The rPFS time is measured from the date of randomization to the earliest date of investigator determined radiographic disease progression (by objective radiographic disease assessment per response evaluation criteria in solid tumors (RECIST) version 1.1 for soft tissue AND/OR radionuclide bone scan using prostate cancer working group 3 -PCWG3 criteria for bone) or death from any cause, whichever occurs first.

Progression-Free Survival (PFS)
Randomization to the date of first documented progression of disease or death from any cause (Up to 21 Months)

PFS defined as the time from the date of randomization to the first evidence of disease progression as defined by response evaluation criteria in solid tumors (RECIST) v1.1 or death from any cause. Progressive Disease (PD) was at least a 20% increase in the sum of the diameters of target lesions, with reference being the smallest sum on study and an absolute increase of at least 5 mm, or unequivocal progression of non-target lesions, or 1 or more new lesions. If a participant does not have a complete baseline disease assessment, then the PFS time was censored at the date of randomization, regardless of whether or not objectively determined disease progression or death has been observed for the participant. If a participant was not known to have died or have objective progression as of the data inclusion cutoff date for the analysis, the PFS time was censored at the last adequate tumor assessment date.

To determine the progression-free survival of patients treated with abemaciclib versus placebo
5 years

PFS is defined as the duration of time from start of treatment to time of progression or death, whichever occurs first.

Invasive Disease Free Survival (IDFS)
Baseline to Recurrence or Death from Any Cause (Up to 32 Months)

IDFS, as defined by the STEEP System, was measured from the date of randomization to the date of first occurrence of one of the following events: ipsilateral invasive breast tumor recurrence, regional invasive breast cancer recurrence, distant recurrence, contralateral invasive breast cancer, second primary non-breast invasive cancer, death attributable to any cause.

Progression Free Survival (PFS) (Abemaciclib + NSAI & Placebo NSAI)
Randomization to Measured Progressive Disease or Death (up to 26 Months)

Progression-free survival time was measured from randomization until the date of objective progression as defined by Response Evaluation Criteria in Solid Tumors v1.1 (RECIST v1.1), or death from any cause. PD is defined as at least a 20% increase in the sum of the diameters of target lesions, with reference being the smallest sum on study and an absolute increase of at least 5 mm, or unequivocal progression of non-target lesions, or 1 or more new lesions. Patients who have neither progressed nor died were censored at the day of their last radiographic tumor assessment, if available, or date of randomization if no post-baseline radiographic assessment is available.

Progression Free Survival (PFS)
Randomization to Progressive Disease or Death Due to Any Cause (Up to 32 Months)

PFS defined as the time from the first day of therapy to the first evidence of disease progression as defined by RECIST v1.1 or death from any cause. Progressive Disease (PD) was at least a 20% increase in the sum of the diameters of target lesions, with reference being the smallest sum on study and an absolute increase of at least 5 mm, or unequivocal progression of non-target lesions, or 1 or more new lesions. If a participant does not have a complete baseline disease assessment, then the PFS time was censored at the date of randomization, regardless of whether or not objectively determined disease progression or death has been observed for the participant. If a participant was not known to have died or have objective progression as of the data inclusion cutoff date for the analysis, the PFS time was censored at the last adequate tumor assessment date.

Overall Survival (OS)
From Randomization Date to Date of Death from Any Cause (Up to 32 Months)

OS defined as from randomization date to the date of death due to any cause. For each participant who is not known to have died as of the data-inclusion cutoff date for overall survival analysis, OS time was censored on the last date the participant is known to be alive.

Proportion of participants who receive an adaptive clinical treatment (ACT) therapy based serial measurements of molecular and architectural responses to therapy (SMMART)-ACT tumor board recommendation
From SMMART-ACT tumor board review to the first dose of ACT study drug per unique treatment regimen. This is expected to take up to approximately 30 days.

A threshold of the posterior probability rate of 75% will be utilized for declaring feasibility to support the analysis of the primary objective in this pilot.

12-week overall response rate (ORR)
12 weeks

Complete response (CR) or partial response (PR), during the first 12 weeks of treatment as per blinded independent central review, using Response Evaluation Criteria in Solid Tumors (RECIST) version (v) 1.1.

Progression-Free Survival Characteristics Over 24 Months
Date of randomization to date of protocol-defined disease progression, assessed up to 24 months

Progression-free survival at 24 months (PFS24) will be analyzed using Kaplan-Meier methods.

Event Free Survival as Determined by Blinded Independent Review Committee
Baseline up to approximately 11 months

Event free survival as determined by blinded independent review committee.

Median Progression Free Survival (PFS)
Up to 2 years

PFS is defined as the time from the date the participant was registered to the date of documented progressive disease (PD) by RECIST version 1.1 or death (regardless of cause) in the absence of progression, regardless of whether the participant withdraws from study drug or receives another anti-cancer therapy prior to progression. Participants alive without disease progression are censored at date of last disease evaluation. A participant who dies without progression, and the death is \>12 weeks after the last evaluable tumor assessment, is censored for PFS at the date of last disease evaluation. A participant who has no baseline or no post treatment tumor assessment is censored at 0 days for PFS, unless she dies \< 12 weeks from randomization, in which case the PFS event date is the death date. Per RECIST 1.1 for target lesions: PD is at least a 20% increase in sum, taking as reference the smallest sum on study with at least 5 mm absolute increase.

Number of participants with disease control at 16 weeks
Week 16

Disease control rate at week 16 in all patients (cohorts A, B, C and D combined) treated at the selected dose level. DCR is defined as the proportion of patients that present with stable disease, partial response or complete response per RECIST 1.1 at 16 weeks after treatment initiation.

The overall response rate (ORR) of the combination of abemaciclib and letrozole, according to Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST v1.1)
Week 24

RECIST is a standard system to measure how cancer responds to different treatments, including chemotherapy, immunotherapy, and radiation therapy.

Composite Endpoint: Number of Participants With Abemaciclib Discontinuation for Any Reason, Abemaciclib Dose Reductions, or the Inability of Study Participants to Reach the Target Dose of Abemaciclib (Full Dose 150 mg BID) at 3 Months (12 Weeks)
3 months (12 weeks)

The composite endpoint is the number and proportion of participants with abemaciclib discontinuation for any reason and/or abemaciclib dose reductions and/or the inability of study participants to reach the target dose of abemaciclib (full dose 150 mg BID) at 3 months (12 weeks).

Progression Free Survival (PFS) Assessed by Blinded Independent Review Committee (BIRC) by Bayesian Analysis
From Date of Randomization until Disease Progression or Death Due to Any Cause (Up to 22.36 months)

PFS was defined as the time from randomization until the first occurrence of documented disease progression per Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST v1.1) criteria, or death from any cause in absence of progressive disease, whichever came first. Progressive disease (PD) was defined as at least 20% increase in the sum of the diameters of target lesions, with reference being the smallest sum on study and an absolute increase of at least 5 millimeter (mm), or unequivocal progression of non-target lesions, or 1 or more new lesions. An event was considered when tumor progression or death occurred, with event date being the earliest date of PD or death. Participants known to be alive and without tumor progression were censored at date of their last adequate tumor assessment per RECIST v1.1 criteria, or date of randomization (whichever was later). Results were obtained using Bayesian analysis and are reported as posterior mean along with its 80% credible interval.

PFS Assessed by BIRC by Frequentist Analysis
From Date of Randomization until Disease Progression or Death Due to Any Cause (Up to 22.36 months)

PFS was defined as the time from randomization until the first occurrence of documented disease progression per RECIST v1.1 criteria, or death from any cause in absence of progressive disease, whichever came first. PD was defined as at least 20% increase in the sum of the diameters of target lesions, with reference being the smallest sum on study and an absolute increase of at least 5 mm, or unequivocal progression of non-target lesions, or 1 or more new lesions. An event was considered when tumor progression or death occurred, with the event date being the earliest date of PD or death. Participants known to be alive and without tumor progression were censored at the date of their last adequate tumor assessment per RECIST v1.1 criteria, or date of randomization (whichever was later). Results were obtained using frequentist analysis.

6-month Progression Free Survival (PFS) Rate
6 months

The percentage of participants alive and progression-free at 6 months, as assessed by RECIST 1.1 and PCWG3.

Objective Response Rate (ORR)
6 months

The percentage of evaluable patients who had radiographic response (complete response or partial response) by RECIST 1.1 criteria OR 50% decline in PSA from pretreatment baseline per PCWG3 criteria.

Number of Participants Experiencing Dose Limiting Toxicity (DLT) in Biomarker-Unselected Abemaciclib + Atezolizumab (Randomized) and CDK12 Mutation Abemaciclib + Atezolizumab (Non-Randomized) Arms
DLTs were collected while participants on treatment. Treatment duration up to 18 months.

DLT was assessed by Bayesian Continuous Toxicity Monitoring in Biomarker-Unselected Abemaciclib + Atezolizumab (Randomized) and CDK12 Mutation Abemaciclib + Atezolizumab (Non-Randomized) arms.

Percentage of Participants With Confirmed Objective Response (Objective Response Rate [ORR])
From Date of First Dose until Objective Progression (Up To 12.8 Months)

ORR is defined as the percentage of participants with a confirmed complete response (CR) or confirmed partial response (PR) in soft tissue per response evaluation criteria in solid tumors (RECIST) version 1.1 and do not have concurrent bone progression per Prostate Cancer Clinical Trials Working Group 3 (PCWG3), as assessed by the investigator. ORR = (participants with confirmed CR and no bone progression) + (participants with confirmed PR and no bone progression) x 100 / all treated participants.

Progression Free Survival at 6 months
6 months

Rate of Progression Free Survival at 6 months on the combination.

Progression-free survival
From date of protocol entry to date of first documented progression up to 6 months

To evaluate the efficacy in terms of the probability of surviving progression free for at least 6 months (PFS at 6 mo)

Percentage of Participants With Severe Diarrhea (≥ Grade 3)
Cycle 3 (28 Days Cycle)

Percentage of participants with severe diarrhea (≥ grade 3) during the first 3 cycles. Events were as assessed by the investigator and graded according to Common Terminology Criteria for Adverse Events (CTCAE). Grade 3 was defined as an increase of ≥7 stools per day over baseline; incontinence; hospitalization indicated; severe increase in ostomy output compared to baseline; limiting self-care activities of daily living (ADL).

Percentage of Participants With Prolonged Grade 2 Diarrhea
Cycle 3 (28 Days Cycle)

Percentage of participants with prolonged grade 2 diarrhea during first 3 cycles. Events were as assessed by the investigator and graded according to Common Terminology Criteria for Adverse Events (CTCAE). Prolonged Grade 2 diarrhea was any event lasting more than 7 days. Grade 2 was defined as Increase of 4-6 stools per day over baseline; moderate increase in ostomy output compared to baseline.

Percentage of Participants With Dose Reductions Due to Diarrhea
Cycle 3 (28 Days Cycle)

Percentage of participants with dose reductions due to diarrhea during first 3 cycles.

Percentage of Participants With Dose Interruptions Due to Diarrhea
Cycle 3 (28 Days Cycle)

Percentage of participants with dose interruptions due to diarrhea during first 3 cycles.

Percentage of Participants Who Discontinue Treatment Due to Diarrhea
Cycle 3 (28 Days Cycle)

Percentage of participants who discontinue treatment due to diarrhea

Percentage of Participants Utilizing Antidiarrheals
Cycle 3 (28 Days Cycle)

Percentage of participants who utilized anti diarrheals at least once during the first 3 cycles.

Radiographic Progression Free Survival (rPFS)
From Date of Randomization to Radiographic Disease Progression or Death from Any Cause (Up to 60 Months)

The rPFS time is measured from the date of randomization to the earliest date of investigator determined radiographic disease progression (by objective radiographic disease assessment per response evaluation criteria in solid tumors (RECIST) version 1.1 for soft tissue AND/OR radionuclide bone scan using prostate cancer working group 3 -PCWG3 criteria for bone) or death from any cause, whichever occurs first.

Progression-Free Rate
4 months

proportion of patients who are alive and progression-free at 4 months on both arms.

Intratumoral Abemaciclib Concentration
Single time point for each participant for collection of tissue and blood at surgery

Intratumoral abemaciclib concentration defined as the mean tumor-to-plasma ratio in contrast enhancing tissue. Patients were treated with abemaciclib prior to surgery. Tissue and plasma for analysis of this endpoint were obtained at the time of surgery.

6-Month Progression Free Survival (PFS6)
6 months

The primary endpoint for the nonsurgical cohort was six-month progression free survival (PFS6). Progression is defined by Response Assessment in Neuro-Oncology criteria for high-grade glioma (RANO-HGG) as \> 25% increase in sum of the products of perpendicular diameters of enhancing lesions (over best response or baseline if no decrease) on stable or increasing doses of corticosteroids AND/OR one or more of the following: significant increase in T2/FLAIR non-enhancing lesion on stable or increasing doses of corticosteroids steroids compared to baseline scan or best response following initiation of therapy, not due to co-morbid events (radiation therapy, demyelination, ischemic injury, infection, seizures, post-operative changes, or other treatment effects); any new lesion; clear clinical deterioration not attributable to other causes apart from the tumor; or failure to return for evaluation due to death or deteriorating condition.

Stage 1: Disease Control Rate (DCR): Percentage of Participants With a Best Overall Response of Complete Response (CR), Partial Response (PR) or Stable Disease (SD)
Baseline to Measured Progressive Disease or Start of New Anticancer Therapy (Up to 6 Months)

Disease control rate (DCR) is the percentage of participants with a best overall response of CR, PR or SD as defined by RECIST v1.1. CR is defined as the disappearance of all target and non-target lesions and no appearance of new lesions. PR is defined as at least a 30% decrease in the sum of the longest diameter (LD) of target lesions (taking as reference the baseline sum LD), no progression of non-target lesions, and no appearance of new lesions. SD is neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for progressive disease (PD) for target lesions, no progression of non-target lesions, and no appearance of new lesions. PD is defined as at least a 20% increase in the sum of the diameters of target lesions, with reference being the smallest sum on study and an absolute increase of at least 5 mm, or unequivocal progression of non-target lesions, or 1 or more new lesions.

Stage 2: Progression Free Survival (PFS)
Baseline to Measured Progressive Disease or Death Due to Any Cause (Up to 6 Months)

PFS was defined as the time from the date of randomization until first observation of objective progressive disease as defined by RECIST v1.1 or death from any cause, whichever comes first. PD is defined as at least a 20% increase in the sum of the diameters of target lesions, with reference being the smallest sum on study and an absolute increase of at least 5 mm, or unequivocal progression of non-target lesions, or 1 or more new lesions. If a patient does not have a complete baseline disease assessment, then the PFS time will be censored at the randomization date, regardless of whether or not objectively determined disease progression or death has been observed for the patient; otherwise, if a patient is not known to have died or have objective progression as of the data inclusion cutoff date for the analysis, the PFS time will be censored at the last complete objective progression-free disease assessment date.

Percent Change From Baseline to 2 Weeks in Ki67 Expression
Baseline, 2 Weeks

Tumor tissue collected through a core biopsy at baseline and at the end of cycle 1 was used to determine Ki67 expression. Ki67 expression is defined as the percent of cells staining positive by validated central assay.

Percentage of Participants Achieving Complete Response (CR) or Partial Response (PR): Objective Intracranial Response Rate (OIRR)
Baseline to Objective Disease Progression (Up to 36 Months)

OIRR is the percentage of participants with a (CR) or (PR) based on the Response Assessment in Neuro-Oncology Brain Metastasis (RANO-BM) response criteria. CR is measurable target lesions, the disappearance of all central nervous system (CNS) target lesions for at least 4 weeks; no new lesions; no corticosteroids; stable or improved clinically. PR is at least a 30% decrease in the sum longest duration (LD) of CNS target lesions, taking as reference the baseline sum LD for at least 4 weeks; no new lesions; stable to decreased corticosteroid dose; stable or improved clinically. Nontarget lesions requires disappearance CNS non-target lesions and no new CNS lesions. Stable disease (SD) is less than (\<)30% decrease relative to baseline but \<20% increase in sum LD relative to nadir. Progressive disease (PD) is greater than or equal to (≥) 20% increase in sum LD relative to nadir and a relative increase of 20%, ≥1 lesion must increase by absolute value of ≥5 millimeter (mm).

Percentage of Participants With Complete Response (CR) or Partial Response (PR) (Objective Response Rate [ORR])
From Date of First Dose until Disease Progression or Death Due to Any Cause (Up To 14 Months)

ORR was the percentage of participants achieving a best overall response (BOR) of complete response (CR) or partial response (PR) as per Response Evaluation Criteria in Solid Tumors (RECIST) v1.1. CR defined as the disappearance of all target and non-target lesions and no appearance of new lesions. PR defined as at least a 30% decrease in the sum of the longest diameters (LD) of target lesions (taking as reference the baseline sum LD), no progression of non-target lesions, and no appearance of new lesions.

Percentage of Participants Who Achieve Disease Control Rate (DCR) Which Includes Complete Response (CR), Complete Response Unconfirmed (CRu), Partial Response (PR) or Stable Disease (SD)
From Date of First Dose until Disease Progression or Death or Start of New Anticancer Therapy (Up to 28 Months)

The DCR was estimated based on the Response Criteria for Non-Hodgkin's Lymphomas (Cheson et al. 1999). DCR was assessed from date of first dose until disease progression or death or start of new anticancer therapy. CR is defined as the disappearance of all detectable clinical and radiographic evidence of disease and disappearance of all disease-related symptoms based on CT scan or bone marrow biopsy; CRu = the CR criteria is met and a residual lymph node mass greater than 1.5 cm in greatest transverse diameter that has regressed by more than 75% in the sum of the product diameter (SPD). PR is \>= 50% decrease in SPD of the six largest nodal masses/no new sites of disease. Progressive Disease (PD) is defined as an increase by 25% in longest diameter, new lesion or assessable disease progression. SD=small changes not meeting the above criteria; DCR and its exact 95% confidence interval (CI) was estimated for treated participants using the Clopper-Pearson method.

Incidence of dose limiting toxicities (DLTs) for the proposed combination
First dose of study agents to end of cycle 1 for dose-determining phase (each cycle is 28 days)

Dose-limiting toxicities will specifically be reported for the DLT evaluation period using the MTD-evaluable population.

Incidence of adverse events (AEs) and serious AEs for the proposed combination
Up to 90 days from last dose of study agent (up to 7 months)

Adverse events will be tabulated by the Medical Dictionary for Regulatory Activities (MedDRA version 21.1) preferred term and system organ class and a preferred term. The severity of the AEs will be assessed by National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) version 5.0 criteria. Descriptive statistics using the safety evaluable population will be used to report on all on-study AEs, grade 3-4 AEs, treatment-related AEs, grade 3-4 treatment-related AEs, serious adverse events (SAEs), treatment-related SAEs, and AEs leading to discontinuation per CTCAE v5.0. Grade 3-4 laboratory abnormalities will be summarized using worst grade NCI CTCAE v 5.0 criteria.

Recommended phase 2 dose of abemaciclib in combination with radiation
Up to 28 days
Recommended phase 2 dose (Part A)
6 weeks

If two or more patients in a cohort experience a dose-limiting toxicity (DLT), then the maximum tolerated dose (MTD)has been exceeded. The previous dose level will be considered the MTD and the recommended phase 2 dose. Per Investigator discretion, the recommended phase 2 dose/schedule of abemaciclib followed by 177Lu-PSMA-617 may be established in the absence of reaching MTD, based on the cumulative safety data of the treatment regimen.

Proportion of participants with DLTs (Part A)
6 weeks

Any non-hematologic, treatment-related adverse event (TRAE) Grade 3+, except of Grade 3 nausea,vomiting,diarrhea,constipation,fever,fatigue,skin rash,alopecia or non-clinically significant laboratory that resolves to Grade \<3 within 72 hours;Grade 4 thrombocytopenia lasting \>7 days;Grade 3+ thrombocytopenia with bleeding/requirement for platelet transfusion;Grade 4 neutropenia lasting \>7 days; Grade 3+ neutropenic fever;Grade 4+ anemia;TRAE requiring treatment discontinuation/delay of \>42 days;Failure to receive at least 66% of abemaciclib doses due to toxicity;Death not clearly due to underlying disease/extraneous causes;Hy's law;Grade 3+ nausea/vomiting/diarrhea \>72 hours;Grade 3+ fatigue \>7 days;Grade 3+ electrolyte abnormality \>72 hours, unless patient has clinical symptoms;All AEs of specified grades should count as DLTs except those that are clearly due to progression/extraneous causes.

Change in maximum standardized uptake value (SUVmax) across three lesions on gallium Ga 68 gozetotide (68Ga-PSMA-11) positron emission tomography (PET) scan (Part B)
Up to 24 weeks

The uptake in the three lesions with the highest SUVmax on the initial scan will be compared to SUVmax measurements in the same lesions on the PSMA PET scan following 14 days of priming treatment with abemaciclib

Recommended Phase 2 Dose (RP2D) of Abemaciclib in Combination With Irinotecan and Temozolomide (Part A)
Cycles 1 and 2 (21 Day Cycles)

The RP2D of abemaciclib was determined based on the totality of safety, tolerability, and pharmacokinetic results. RP2D of abemaciclib in combination with 50 mg/m²/day irinotecan and 100 mg/m²/day temozolomide on days 1-5 of 21-day cycles was reported.

Number or Participants With Dose Limiting Toxicities (DLTs) in Part A
Cycle 1 (21 Day Cycle)

DLT was 1 of the following adverse events likely related to abemaciclib/combination and fulfils any 1 of the following criteria graded per National Cancer Institute-Common Terminology Criteria for Adverse Events (NCI-CTCAE) v5.0: * Any non-hematologic Grade (G) ≥3 toxicity, except: * G3 diarrhea lasting \<72 hour (h) * Acute irinotecan-associated diarrhea lasting \<7 days * G≥3 nausea, vomiting, constipation that lasts \<72 h * G3 mucositis/stomatitis lasting \<72 h * G3 fever/infection * G≥3 electrolyte abnormality that lasts \<72 h, is not complicated, and resolves spontaneously or responds to conventional medication; * G≥3 amylase/lipase that is not associated with symptoms/clinical manifestations of pancreatitis; or * AST/ALT elevation resolving to eligibility criteria within 7 days; * Hematologic toxicities considered a DLT: * A \>14-day Cycle 2 delay due to neutropenia/thrombocytopenia * G≥3 thrombocytopenia with significant bleeding; or * G≥ 4 neutropenic fever

Maximum Tolerated Dose (MTD) of Abemaciclib in Part A
Cycle 1 (21 Days)

The MTD was defined as the highest dose level at which less than 33% of participants experienced a DLT.

Pharmacokinetics (PK): Area Under the Concentration Versus Time Curve From Time Zero to Tlast (AUC0-tlast) of Abemaciclib in Part A
Pre-dose, 1, 2.5, 4, and 6 hours post Day 1 dose of Cycle 1 and Cycle 2 (21 Day Cycle)

PK: (AUC0-tlast) was reported.

PK: (AUC0-tlast) of Irinotecan in Part A
2.5, 4, and 6 hours post Day 1 dose of Cycle 1 and Cycle 2 (21 Day Cycle)

PK: AUC0-tlast) was reported.

PK: (AUC0-tlast) of Temozolomide in Part A
1, 2.5, 4, and 6 hours post Day 1 dose of Cycle 1 and Cycle 2 (21 Day Cycle)

PK: AUC0-tlast was reported.

RP2D of Abemaciclib in Combination With Temozolomide (Part B)
Cycles 1 and 2 (21 Day Cycles)

The RP2D of abemaciclib was determined based on the totality of safety, tolerability, and pharmacokinetic results. RP2D of abemaciclib in combination with 150 mg/m²/day temozolomide on days 1-5 of 21-day cycles was reported.

Number or Participants With DLTs in Part B
Cycle 1 (21 Day Cycle)

A DLT was 1 of the following adverse events likely related to abemaciclib/combination and fulfils any 1 of the following criteria graded as per National Cancer Institute-Common Terminology Criteria for Adverse Events (NCI-CTCAE) v5.0: * Any non-hematologic Grade (G) ≥3 toxicity, except: * G3 diarrhea lasting \<72 hr * Acute irinotecan-associated diarrhea lasting \<7 days * G≥3 nausea, vomiting, constipation that lasts \<72 hr * G3 mucositis/stomatitis lasting \<72 hr * G3 fever/infection * G≥3 electrolyte abnormality that lasts \<72 hr, is not complicated, and resolves spontaneously or responds to conventional medication; * G≥3 amylase/lipase that is not associated with symptoms/clinical manifestations of pancreatitis; or * AST/ALT elevation resolving to eligibility criteria within 7 days; * Hematologic toxicities considered a DLT: * A \>14-day Cycle 2 delay due to neutropenia/thrombocytopenia * G≥3 thrombocytopenia with significant bleeding; or * G≥ 4 neutropenic fever

MTD of Abemaciclib in Part B
Cycle 1 (21 Days)

The MTD was defined as the highest dose level at which less than 33% of participants experienced a DLT.

PK: AUC0-tlast of Abemaciclib in Part B
Pre-dose, 1, 2.5, 4, and 6 hours post Day 1 dose of Cycle 1 and Cycle 2 (21 Day Cycle)

PK: AUC0-tlast was reported.

PK: AUC0-tlast of Temozolomide in Part B
1, 2.5, 4, and 6 hours post Day 1 dose of Cycle 1 and Cycle 2 (21 Day Cycle)

PK: AUC0-tlast was reported.

Number of Participants With Overall Response Rate (ORR) in Part C.
Date of first dose to disease progression or death (Up to 25 Months)

ORR: Number of participants with best response of Complete Response (CR), Partial Response (PR), or Minor Response (MR) per International Neuroblastoma Response Criteria (INRC). * CR is defined as complete response in all response components: * Primary Tumor: \<10 mm residual soft tissue primary site and complete resolution of MIBG-avid tumors * Soft tissue and bone metastatic response: nonprimary target and nontarget lesions \<10 mm and nodes identified as targets decreased to short axis \<10mm and MIBG-avid update of nonprimary lesions completely resolved * Bone marrow response: no tumor infiltration on reassessment; disappearance of all target lesions; * PR is defined as PR in \>1component and all other components are either CR, minimal disease (MD) (bone marrow only), PR (soft tissue or bone), or not involved (NI) and no components with progressive disease (PD). * MR is defined PR or CR in \>1 component and SD in \>1 component and no component with PD

Pharmacokinetics (PK): Area Under the Concentration Versus Time Curve From Time Zero to Infinity (AUC[0-∞]) of LY3819253
Days 1, 2, 3, 4, 5, 6, 7, 15, 29, 60, 85 post-dose

PK: AUC\[0-∞\] of LY3819253

Number of Participants with Dose Limiting Toxicities (DLTs)
Baseline through Cycle 1 (28 Day Cycle)

Number of Participants with DLTs

Number of Participants With One or More Drug Related Adverse Events
Baseline through End of Study (Up to 10 Months)

Number of participants with one or more drug related adverse events. Clinically significant events were defined as serious adverse events, regardless of causality. A summary of serious and other non-serious adverse events regardless of causality is located in the Reported Adverse Event module.

Number of Participants with One or More Serious Adverse Event(s) (SAEs)
Baseline through Study Treatment Completion (Approximately 6 Months)
Number of Participants with Non-Serious Adverse Event(s)
Baseline through Study Treatment Completion (Approximately 6 Months)
Pharmacokinetics (PK): Area Under the Concentration Versus Time Curve From Time Zero to Infinity (AUC[0-∞]) of Metformin
Pre dose, 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 8, 10, 12, 24, 36 hours (h) post dose

Pharmacokinetics (PK): Area Under the Concentration Versus Time Curve from Time Zero to Infinity (AUC\[0-∞\]) of Metformin was evaluated.

Pharmacokinetics (PK): Maximum Observed Drug Concentration (Cmax) of Metformin
Pre dose, 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 8, 10, 12, 24, 36 hours (h) post dose

Pharmacokinetics (PK): Maximum Observed Drug Concentration (Cmax) of Metformin was evaluated.

Pharmacokinetics (PK): Renal Clearance (CLr) of Metformin
Pre dose, 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 8, 10, 12, 24, 36 hours (h) post dose

Pharmacokinetics (PK): Renal Clearance (CLr) of Metformin was evaluated.

Pharmacokinetics (PK): Area Under the Concentration Versus Time Curve From Zero to Infinity (AUC[0-∞])
Parts A and C Periods 1 and 2; Part B Periods 1, 2, 3: Predose, 0.5, 1, 2, 3, 4, 6, 8, 10, 12, 24, 48, 96, 120,144,168 and 192 hours postdose

Area under the concentration versus time curve from zero to infinity.

PK: Maximum Observed Drug Concentration (Cmax)
Parts A and C Periods 1 and 2; Part B Periods 1, 2, 3: Predose, 0.5, 1, 2, 3, 4, 6, 8, 10, 12, 24, 48, 96, 120,144,168 and 192 hours postdose

Maximum observed drug concentration.

Mean Time Matched Placebo-Adjusted Changes From Baseline For Fridericia's Corrected QT Interval (ΔΔQTcF)
Day 1: 2hr,4hr,6hr,8hr,10hr,12hr,14hr,24hr Post Dose

QT interval is a measure of the time between the start of the Q wave and the end of the T wave and was calculated from electrocardiogram (ECG) data. ECG monitoring was conducted using a 12-lead digital Holter recorder from approximately 2 hours predose through 24 hours postdose on Day 1 of each period using 12-lead digital Holter recorder. Fridericia-corrected QT interval (QTcF): QTcF = QT/RR1/3, where RR is the interval between two R waves.

Pharmacokinetics: Area Under the Concentration Versus Time Curve From Time Zero to Infinity (AUC [0-inf]) for Both Fed and Fasted Periods for Abemaciclib and Major Metabolites
Day 1: Predose, 0.5, 1, 2, 3, 4, 6, 8, 10, 12, 24, 48, 72, 96, 120, 144, 168, and 192 Hours Postdose in Each Period
Pharmacokinetics: Maximum Concentration (Cmax) for Both Fed and Fasted Periods for Abemaciclib and Major Metabolites
Day 1: Predose, 0.5, 1, 2, 3, 4, 6, 8, 10, 12, 24, 48, 72, 96, 120, 144, 168, and 192 Hours Postdose in Each Period
Pharmacokinetics (PK): Maximum Observed Concentration (Cmax) of Abemaciclib and Active Metabolites
Day 1: Predose, 1, 2, 3, 4, 6, 8, 10, 24, 48, 72, 96, 120, 144, 168, and 192 Hours Postdose
Pharmacokinetics (PK): Area Under the Concentration Versus Time Curve From Time Zero to Infinity(AUC[0-inf]) of Abemaciclib and Active Metabolites
Day 1: Predose, 1, 2, 3, 4, 6, 8, 10, 24, 48, 72, 96, 120, 144, 168, and 192 Hours Postdose
Pharmacokinetics (PK): Area Under the Concentration Time Curve From Zero to Infinity (AUC[0-∞]) of Abemaciclib
Period 1: Predose; 1, 2, 4, 6, 8, 10, 24, 48, 72, 96, 120, 144, 168hr, Period 2: 1, 2, 4, 6, 8, 10, 24, 48, 72, 96, 120, 144, 168, 192, 216, 240hr Post dose
PK: Maximum Concentration (Cmax) of Abemaciclib
Period 1: Predose; 1, 2, 4, 6, 8, 10, 24, 48, 72, 96,120,144,168hr, Period 2: 1, 2, 4, 6, 8, 10, 24, 48, 72, 96, 120, 144, 168, 192, 216, 240hr Post dose
Number of Participants With Dose-Limiting Toxicities (DLT) or DLT-equivalent in Part A, B, C, D and E
Baseline through study completion (Up To 15 Months)

A DLT defined as adverse event(AE) occurring between Day 1 and Day 21 of Cycle 1 that was considered at least possibly related to either abemaciclib or the combination therapy and fulfilled a criteria selected (using the National Cancer Institute Common Terminology Criteria for Adverse Events,version 4.0 \[NCI-CTCAE v 4.0\] \[NCI 2009\]):Grade(Gr)≥3 nonhematological toxicity,Gr4 thrombocytopenia lasting at least 5 days and/or complicated with bleeding,Gr≥3 febrile neutropenia(ntr) and for Part D participants (pts): Gr3 hyperglycemia (fasting) of \<5 days, Gr3 hypertriglyceridemia or hyperlipidemia without optimal treatment.A DLT-equivalent defined as AE that would have met the criteria for DLT if it had occurred during Cycle 1 for pts enrolled in dose-escalation phase,but that occurs between 1)Day 1 and Day 21 of Cycle 2 and beyond for a participant enrolled in dose-escalation phase 2) at any time for a participant in dose-expansion phase.

Number of Participants With Clinically Significant Effects
Baseline up to 233 weeks

The number of participants with clinically significant findings in the study were reported in this outcome measure.

Phase 0: Pharmacokinetic analysis of tumor tissue
8 hour

Total and Unbound LY3214996 and Abemaciclib (and related M2 and M20 metabolites) concentration in enhancing and non-enhancing tumor tissue

Phase 0: Pharmacokinetic analysis of cerebrospinal fluid (CSF)
8 hour

Total and Unbound LY3214996 and Abemaciclib (and related M2 and M20 metabolites) concentration in CSF

Pharmacokinetic analysis of plasma
Day 6 at 0, 0.5, 1, 2, 4, 6, 8, 12 and 24 hours post dose

Total and Unbound LY3214996 and Abemaciclib (and related M2 and M20 metabolites) concentration in plasma

Phase 2: Progression-free survival
up to 60 months

Phase 2: 6-month progression-free survival (PFS6) rate measured from time of surgery to date of recurrence

Secondary Endpoints
Radiographic Progression-Free Survival (rPFS) Assessed by Blinded Independent Central Review (BICR)
From Date of Randomization to Radiographic Disease Progression or Death from Any Cause (up to 22 months)
Castration-resistant Prostate Cancer (CRPC)-Free Survival
Randomization to the earliest date of PSA or radiographic progression with a testosterone level of ≤50 ng/dL; or death from any cause (up to 22 months)
Overall Survival (OS)
From Date of Randomization to Date of Death Due to Any Cause (Up to 22 Months)
Unlock Study Endpoints
Study Design & Arms
AllocationRANDOMIZED
MaskingDOUBLE
ModelPARALLEL
PurposeTREATMENT
Treatment Arms
ArmTypeDescription
AbemaciclibEXPERIMENTALParticipants received 200 milligram (mg) abemaciclib twice daily (BID) in combination with standard doses of 1000 mg abiraterone acetate once daily and 5mg prednisone BID administered orally on a continuous dosing schedule on days 1 through 28 of a 28-day cycle until radiographic and/or symptomatic progression or until another discontinuation criterion is met.
PlaceboACTIVE_COMPARATORParticipants received placebo BID in combination with standard doses of 1000 mg abiraterone acetate once daily and 5mg prednisone BID administered orally on a continuous dosing schedule on days 1 through 28 of a 28-day cycle until radiographic and/or symptomatic progression or until another discontinuation criterion is met.
Arm A: Abemaciclib plus FulvestrantEXPERIMENTALAbemaciclib 150 milligram (mg) administered orally twice daily (BID) on Days 1 to 28 of a 28-day cycle in combination with fulvestrant 500 mg administered intramuscularly (IM) on Days 1 and 15 of Cycle 1, then on Day 1 of Cycle 2 and beyond. Participants received treatment until discontinuation criteria were met.
Arm B: Placebo plus FulvestrantACTIVE_COMPARATORPlacebo administered orally BID on Days 1 to 28 of a 28-day cycle in combination with fulvestrant 500 mg administered IM on Days 1 and 15 of Cycle 1, then on Day 1 of Cycle 2 and beyond. Participants received treatment until discontinuation criteria were met.
Placebo ArmPLACEBO_COMPARATORPatients will be randomized 1:1 and will receive placebo if they are randomized to the placebo arm of the study. Each cycle is 28 days.
150 mg Abemaciclib + Endocrine TherapyEXPERIMENTALParticipants received Abemaciclib orally at 150 milligrams (mg) twice daily with at least 6 hours between doses for up to 2 years or until evidence of disease recurrence or other discontinuation criteria were met, whichever occurs first. Endocrine therapy (physicians' choice) standard-of-care was administered according to package label until discontinuation criteria were met.
Endocrine TherapyOTHEREndocrine therapy (physicians' choice) standard-of-care was administered according to package label until discontinuation criteria were met.
Abemaciclib + Nonsteroidal Aromatase Inhibitor (NSAI)EXPERIMENTALAbemaciclib given orally every 12 hours (Q12H) plus anastrozole or letrozole given orally every 24 hours (Q24H) on days 1 to 28 of a 28 day cycle. Participants receiving benefit may continue until disease progression.
Placebo + NSAIEXPERIMENTALPlacebo given orally Q12H plus anastrozole or letrozole given orally Q24H on days 1 to 28 of a 28 day cycle. Participants receiving benefit may continue until disease progression.
Abemaciclib + FulvestrantEXPERIMENTALAbemaciclib given orally Q12H on days 1 to 28 of a 28 day cycle plus fulvestrant intramuscularly (IM) on days 1 and 15 of cycle 1, then on day 1 of cycle 2 and beyond. Participants receiving benefit may continue until disease progression.
Placebo + FulvestrantEXPERIMENTALPlacebo given orally Q12H on days 1 to 28 of a 28 day cycle plus fulvestrant IM on days 1 and 15 of cycle 1, then on day 1 of cycle 2 and beyond. Participants receiving benefit may continue until disease progression.
Abemaciclib + NSAIEXPERIMENTAL150 milligrams (mg) Abemaciclib orally every 12 hours plus either 1 mg anastrozole or 2.5 mg letrozole orally once daily for 28 days (28 day cycles).
ErlotinibACTIVE_COMPARATOR150 mg erlotinib administered, orally, every 24 hours plus BSC on Days 1 to 28 (28 day cycles).
Arm I (abemaciclib, gemcitabine)EXPERIMENTALPatients receive abemaciclib PO BID on days 1-21 and gemcitabine IV over 30 minutes on days 1 and 8 of each cycle. Cycles repeat every 21 days for up to 8 cycles in the absence of disease progression or unacceptable toxicity. Patients undergo blood sample collection throughout the study. Patients also undergo tumor biopsy on study and optionally at the end of treatment. Additionally, prostate cancer patients undergo bone scan on study.
Arm II (abemaciclib, pemetrexed)EXPERIMENTALPatients receive abemaciclib PO BID on days 1-21 and pemetrexed IV over 10 minutes on day 1 of each cycle. Cycles repeat every 21 days for up to 8 cycles in the absence of disease progression or unacceptable toxicity. Patients undergo blood sample collection throughout the study. Patients also undergo tumor biopsy on study and optionally at the end of treatment. Additionally, prostate cancer patients undergo bone scan on study.
Arm III (abemaciclib)EXPERIMENTALPatients receive abemaciclib PO BID on days 1-28 of each cycle. Cycles repeat every 28 days for up to 6 cycles in the absence of disease progression or unacceptable toxicity. Patients undergo blood sample collection throughout the study. Patients also undergo tumor biopsy on study and optionally at the end of treatment. Additionally, prostate cancer patients undergo bone scan on study.
Arm IV (abemaciclib, exemestane)EXPERIMENTALPatients receive abemaciclib PO BID and exemestane PO QD on days 1-28 of each cycle. Cycles repeat every 28 days for up to 6 cycles in the absence of disease progression or unacceptable toxicity. Patients undergo blood sample collection throughout the study. Patients also undergo tumor biopsy on study and optionally at the end of treatment. Additionally, prostate cancer patients undergo bone scan on study.
Arm V (abemaciclib, letrozole)EXPERIMENTALPatients receive abemaciclib PO BID and letrozole PO QD on days 1-28 of each cycle. Cycles repeat every 28 days for up to 6 cycles in the absence of disease progression or unacceptable toxicity. Patients undergo blood sample collection throughout the study. Patients also undergo tumor biopsy on study and optionally at the end of treatment. Additionally, prostate cancer patients undergo bone scan on study.
Arm VI (abemaciclib, tamoxifen)EXPERIMENTALPatients receive abemaciclib PO BID and tamoxifen PO QD on days 1-28 of each cycle. Cycles repeat every 28 days for up to 6 cycles in the absence of disease progression or unacceptable toxicity. Patients undergo blood sample collection throughout the study. Patients also undergo tumor biopsy on study and optionally at the end of treatment. Additionally, prostate cancer patients undergo bone scan on study.
Arm VII (gefitinib, pemetrexed, carboplatin)EXPERIMENTALPatients receive gefitinib PO QD on days 1-21, pemetrexed IV on day 1 of each cycle and carboplatin IV on day 1 of cycles 1-6. Cycles repeat every 21 days for up to 8 cycles in the absence of disease progression or unacceptable toxicity. Patients undergo blood sample collection throughout the study. Patients also undergo tumor biopsy on study and optionally at the end of treatment. Additionally, prostate cancer patients undergo bone scan on study.
Arm VIII (olaparib, temozolomide)EXPERIMENTALPatients receive olaparib PO BID and temozolomide PO QD on days 1-7 of each cycle. Cycles repeat every 21 days for up to 8 cycles in the absence of disease progression or unacceptable toxicity. Patients undergo blood sample collection throughout the study. Patients also undergo tumor biopsy on study and optionally at the end of treatment. Additionally, prostate cancer patients undergo bone scan on study.
Arm IX (fulvestrant)EXPERIMENTALPatients receive fulvestrant IM on days 1, 15 and 29 of cycle 1 and day 1 of subsequent cycles. Cycles repeat every 28 days for up to 6 cycles in the absence of disease progression or unacceptable toxicity. Patients undergo blood sample collection throughout the study. Patients also undergo tumor biopsy on study and optionally at the end of treatment. Additionally, prostate cancer patients undergo bone scan on study.
Arm X (gefitinib)EXPERIMENTALPatients receive gefitinib PO QD on days 1-28 of each cycle. Cycles repeat every 28 days for up to 6 cycles in the absence of disease progression or unacceptable toxicity. Patients undergo blood sample collection throughout the study. Patients also undergo tumor biopsy on study and optionally at the end of treatment. Additionally, prostate cancer patients undergo bone scan on study.
Arm XI (olaparib)EXPERIMENTALPatients receive olaparib PO BID on days 1-28 of each cycle. Cycles repeat every 28 days for up to 6 cycles in the absence of disease progression or unacceptable toxicity. Patients undergo blood sample collection throughout the study. Patients also undergo tumor biopsy on study and optionally at the end of treatment. Additionally, prostate cancer patients undergo bone scan on study.
Arm XII (olaparib, carboplatin, paclitaxel)EXPERIMENTALPatients receive olaparib PO BID on days 1-3, 8-10, 15-17, 21-23 and carboplatin IV and paclitaxel IV on days 1, 8 and 15 of each cycle. Cycles repeat every 28 days for up to 6 cycles in the absence of disease progression or unacceptable toxicity. Patients undergo blood sample collection throughout the study. Patients also undergo tumor biopsy on study, as clinically indicated, and optionally at the end of treatment. Additionally, prostate cancer patients undergo bone scan on study.
Arm XIII (olaparib, liposomal doxorubicin)EXPERIMENTALPatients receive olaparib PO BID on days 1-28 and liposomal doxorubicin IV on day 1 of each cycle. Cycles repeat every 28 days for up to 6 cycles in the absence of disease progression or unacceptable toxicity. Patients undergo echocardiography or MUGA scan and blood sample collection throughout the study. Patients also undergo tumor biopsy on study and optionally at the end of treatment. Additionally, prostate cancer patients undergo bone scan on study.
Arm XIV (osimertinib)EXPERIMENTALPatients receive osimertinib PO QD on days 1-28 of each cycle. Cycles repeat every 28 days for up to 6 cycles in the absence of disease progression or unacceptable toxicity. Patients undergo echocardiography or MUGA scan and blood sample collection throughout the study. Patients also undergo tumor biopsy on study and optionally at the end of treatment. Additionally, prostate cancer patients undergo bone scan on study.
Interventional Arm (Arm A)EXPERIMENTALAbemaciclib 150 mg orally twice daily (BID) during each 28 day cycle combined with ET (2.5 mg letrozole, orally administered and taken daily during each 28-day cycle, or 500 mg fulvestrant, by intramuscular \[IM\] administration on Days 1 and 15 (±3 days) of the first treatment cycle and Day 1 of each cycle thereafter.
Control Arm (Arm B)ACTIVE_COMPARATORPaclitaxel 90 mg/m² infused over 1 hour on Days 1, 8, and 15 of the 28 day cycle, with at least a 6-day time span between separated doses.
Active Treatment (Abemaciclib)EXPERIMENTALAdministered twice daily on days 1-28 of each 28-day cycle.
Abemaciclib + Temozolomide - Arm AEXPERIMENTALParticipants will receive abemaciclib administered orally in addition to temozolomide administered orally or intravenously (IV).
Temozolomide - Arm BACTIVE_COMPARATORParticipants will receive temozolomide administered orally or IV.
Arm 1: Abemaciclib + LetrozoleEXPERIMENTALParticipants will be stratified by Primary Stage IVb (4b) vs. Primary Measurable Stage III (3)/IVa (4a) vs. Recurrent Endometrial Cancer and will complete study procedures as follows: * Baseline visit with X-ray, CT, MRI, or PET scan. * Cycles 1 through 3: --Days 1 through 21 of 21 day cycle: Predetermined dose of Abemaciclib 2x per day. Predetermined dose of Letrozole 1x per day. * Cycle 4 and every 2 cycles thereafter: --Days 1 through 21 of 21 day cycle: Predetermined dose of Abemaciclib 2x per day. Predetermined dose of Letrozole 1x per day. * X-ray, CT, MRI, or PET scan every 9 weeks for first 9 months, then every 12 months. * End of Treatment visit with assessments and X-ray, CT, MRI, or PET scan. * Follow up for up to 3 years.
Abemaciclib and bicalutamideEXPERIMENTALParticipants receive Abemaciclib 150 mg tablet orally twice daily and Bicalutamide 150 mg orally once daily until disease progression or unacceptable toxicity.
Abemaciclib and letrozoleEXPERIMENTALParticipants received abemaciclib 150 mg tablet orally twice daily and letrozole tablet 2.5 mg orally once daily until disease progression, unacceptable adverse event(s) or death.
Abemaciclib + Irinotecan +TemozolomideEXPERIMENTALParticipants received the following treatments in a 21-day cycle, continuing until disease progression, unacceptable toxicity, or a criterion for discontinuation was met. * Abemaciclib: 55 mg/m² (milligrams per square meter), administered orally twice daily (BID) for less than (\<18) years or 100 mg administered orally BID for greater than or equal to (≥)18 years. * Irinotecan: 50 mg/m²/day, administered intravenously (IV) on Days 1-5 of each cycle. * Temozolomide: 100 mg/m²/day, administered orally on Days 1-5 of each cycle.
Irinotecan +TemozolomideEXPERIMENTALParticipants received the following treatments in a 21-day cycle, continuing until disease progression, unacceptable toxicity, or a criterion for discontinuation was met. * Irinotecan: 50 mg/m²/day, administered IV on Days 1-5 of each cycle. * Temozolomide: 100 mg/m²/day, administered orally on Days 1-5 of each cycle.
Biomarker-Unselected Abemaciclib Monotherapy (Randomized)EXPERIMENTALParticipants in the Biomarker-Unselected Cohort, defined as those whose tumors are not known to have mutations in the CDK12 gene will be randomized to either receive Abemaciclib as monotherapy or in combination with Atezolizumab * Monotherapy : Participants will receive Abemaciclib orally 2x daily
Biomarker-Unselected Abemaciclib + Atezolizumab (Randomized)EXPERIMENTALParticipants in the Biomarker-Unselected Cohort, defined as those whose tumors are not known to have mutations in the CDK12 gene will be randomized to either receive Abemaciclib as monotherapy or in combination with Atezolizumab * Combination Therapy: Participants will receive Abemaciclib orally 2x daily and Atezolizumab intravenously Day 1 of each 21-Day cycle
CDK12 Mutation Atezolizumab Monotherapy (Non-Randomized)EXPERIMENTALParticipants in the CDK12 Mutation Cohort defined as those whose tumors are known to have mutations in the CDK12 gene are not randomized but are assigned to receive either Atezolizumab monotherapy or in combination with Abemaciclib based on how many participants in this cohort previously received study treatment. Atezolizumab monotherapy will be given to participants 1-5, these participants will receive Atezolizumab intravenously Day 1 of each 21-Day cycle
CDK12 Mutation Abemaciclib + Atezolizumab (Non-Randomized)EXPERIMENTALParticipants in the CDK12 Mutation Cohort defined as those whose tumors are known to have mutations in the CDK12 gene are not randomized but are assigned to receive either Atezolizumab monotherapy or in combination with Abemaciclib based on how many participants in this cohort previously received study treatment. Combination Therapy will be given to participants 6-21, these participants will receive Abemaciclib orally 2x daily and Atezolizumab intravenously Day 1 of each 21-Day cycle
200 milligram (mg) Abemaciclib Twice DailyEXPERIMENTALParticipants received 200 mg abemaciclib administered orally twice daily on a continuous dosing schedule (28-day cycle) until symptomatic and/or radiographic progression, unacceptable toxicity, or until another discontinuation criterion is met.
Single Arm, POCEXPERIMENTALSingle arm, POC Safety and Efficacy Osimertinib 80 mg QD Abemaciclib 150mg BID
Treatment (abemaciclib)EXPERIMENTALPatients receive abemaciclib PO BID on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
200 mg Abemaciclib With a MealEXPERIMENTAL200 mg abemaciclib given twice a day (BID) orally with a meal.
200 mg Abemaciclib Without a MealEXPERIMENTAL200 mg abemaciclib given twice a day (BID) orally without a meal, taken in the modified fasted condition.
200 mg Abemaciclib Without Regard to FoodEXPERIMENTAL200 mg abemaciclib given twice a day (BID) orally without regard for food.
Participants with CCND1, CCND2, or CCND3EXPERIMENTAL* Abemaciclib will be administered orally on a daily basis * Dosage will be determine by the PI
Participants with CDK4 or CDK6EXPERIMENTAL* Abemaciclib will be administered orally on a daily basis * Dosage will be determine by the PI
Abemaciclib with SurgeryEXPERIMENTAL* Abemaciclib will be administered on a continuous twice daily dosing schedule * Patients who require re-operation will receive a short preoperative course of Abemaciclib * Tissue will be used to investigate the ability of Abemaciclib to pass through the blood brain barrier. * After recovery from surgery, participants will resume Abemaciclib. Each cycle lasts 28 days. * NOTE: enrollment to this arm is complete
Abemaciclib without SurgeryEXPERIMENTAL* Abemaciclib will be administered on a continuous twice daily dosing schedule. Each Cycle last 28 days. * NOTE: enrollment to this arm is complete
Cohort 1 Surgery ArmEXPERIMENTALParticipants who require reoperation will be treated with abemaciclib for 10-14 days prior to surgery. Tissue will be used to further investigate the abilities of Abemaciclib. After surgery participants will come off study and pursue standard of care treatments at their treating physician's discretion.
Abemaciclib + LY3023414EXPERIMENTALAbemaciclib given orally and LY3023414 given orally.
Standard of Care (Gemcitabine or Capecitabine)EXPERIMENTALGemcitabine given intravenously (IV) OR capecitabine given orally.
Abemaciclib + TamoxifenEXPERIMENTALAbemaciclib given orally every 12 hours (Q12H) in combination with tamoxifen given orally every day. Participants may continue to receive treatment until discontinuation criteria are met.
Abemaciclib + Prophylactic LoperamideEXPERIMENTALAbemaciclib given orally Q12H in combination with prophylactic loperamide given orally. Participants may continue to receive treatment until discontinuation criteria are met.
150 mg Abemaciclib + 8 mg/kg Trastuzumab + 500 mg FulvestrantEXPERIMENTAL150 milligram (mg) abemaciclib given orally every 12 hours (Q12H) of a 21-day cycle; plus 8 milligram per kilogram (mg/kg) trastuzumab intravenous (IV) infusion on Day 1 of the cycle then a 6 mg/kg maintenance dose IV infusion on Day 1 of each subsequent cycle; plus 500 mg fulvestrant intramuscularly (IM) on day 1, 15 and 29 and then once every 4 weeks thereafter.
150 mg Abemaciclib + 8 mg/kg TrastuzumabEXPERIMENTAL150 mg abemaciclib given orally Q12H of a 21-day cycle; plus 8 mg/kg trastuzumab IV infusion on Day 1 of the cycle then a 6 mg/kg maintenance dose IV infusion on Day 1 of each subsequent cycle.
8 mg/kg Trastuzumab + Standard of Care ChemotherapyACTIVE_COMPARATOR8 mg/kg trastuzumab IV infusion on Day 1 of a 21-day cycle then a 6 mg/kg maintenance dose IV infusion on Day 1 of each subsequent cycle plus standard of care single agent chemotherapy of physician's choice administered according to product label
DocetaxelACTIVE_COMPARATOR75 milligram per meter squared (mg/m²) docetaxel given intravenously (IV) on day 1 of each 21 day cycle. Participants may continue to receive treatment until discontinuation criteria are met.
Abemaciclib + AnastrozoleEXPERIMENTALAbemaciclib (150 milligrams \[mg\]) was given orally every 12 hours (Q12H) plus anastrozole (1 mg) orally once daily (QD) for 2 weeks. Loperamide was given as a prophylaxis for 4 weeks and then at physician discretion. All participants received abemaciclib (150 mg) orally Q12H plus anastrozole (1 mg) QD for an additional 14 weeks. Total treatment duration was 16 weeks.
AnastrozoleACTIVE_COMPARATORAnastrozole (1 mg) is given orally QD for 2 weeks. All participants received abemaciclib (150 mg) orally Q12H plus anastrozole (1 mg) QD for an additional 14 weeks. Loperamide was given as a prophylaxis for the first 2 weeks of the combination treatment and then at physician discretion. Total treatment duration was 16 weeks.
Part A Abemaciclib: HR+, HER2+ Breast CancerEXPERIMENTALAbemaciclib 200 milligram (mg) was administered orally once every 12 hours on days 1-21 of a 21-day cycle when administered as a single agent or in combination with endocrine therapy (ET). Participants with hormone receptor positive (HR+), HER2+ breast cancer receiving concurrent trastuzumab, 150 mg abemaciclib was given orally once every 12 hours on days 1-21 of a 21-day cycle. Participants may continue to receive treatment until discontinuation criteria are met.
Part B Abemaciclib: HR+, HER2- Breast CancerEXPERIMENTALAbemaciclib 200 mg was administered orally once every 12 hours on days 1-21 of a 21-day cycle when administered as a single agent or for participants in combination with endocrine therapy (ET). Participants may continue to receive treatment until discontinuation criteria are met.
Part C Abemaciclib: Surgical ResectionEXPERIMENTALAbemaciclib 200 mg was administered orally once every 12 hours on days 1-21 of a 21-day cycle when administered as a single agent or for participants with breast cancer in combination with endocrine therapy (ET). Participants with HR+, HER2+ breast cancer, NSCLC, or melanoma with intracranial lesions for which surgical resection is clinically indicated receiving concurrent trastuzumab, gemcitabine, or pemetrexed, 150 mg abemaciclib was given orally once every 12 hours for 5-14 days prior to surgical resection. Dosing may resume following wound healing on a 21-day cycle. Participants may continue to receive treatment until discontinuation criteria are met.
Part D Abemaciclib: Non-Small Cell Lung Cancer (NSCLC)EXPERIMENTALAbemaciclib 200 mg was administered orally once every 12 hours on days 1-21 of a 21-day cycle. Participants with NSCLC receiving concurrent gemcitabine or pemetrexed, 150 mg abemaciclib was given orally once every 12 hours on days 1-21 of a 21-day cycle. Participants may continue to receive treatment until discontinuation criteria are met.
Part E Abemaciclib: MelanomaEXPERIMENTALAbemaciclib 200 mg was administered orally once every 12 hours on days 1-21 of a 21-day cycle. Participants may continue to receive treatment until discontinuation criteria are met.
Part F Abemaciclib: HR+ Breast Cancer, NSCLC, or MelanomaEXPERIMENTALAbemaciclib 200 mg was administered orally once every 12 hours on days 1-21 of a 21-day cycle when administered as a single agent or for participants with breast cancer in combination with endocrine therapy (ET). Participants with HR+ (either HER2+ or HER2-) breast cancer, NSCLC, or melanoma and leptomeningeal metastases received concurrent trastuzumab, gemcitabine, or pemetrexed, 150 mg abemaciclib was given orally once every 12 hours on days 1-21 of a 21-day cycle. Participants may continue to receive treatment until discontinuation criteria are met.
Treatment (abemaciclib, niraparib)EXPERIMENTALPatients receive abemaciclib PO BID and niraparib PO QD. Treatment repeats every 28 days for up to 2-4 cycles in the absence of disease progression or unacceptable toxicity. Patients who complete 4 cycles undergo standard of care mastectomy or lumpectomy. Patients demonstrating progressive disease after only 2 cycles are switched to receive standard of care chemotherapy prior to undergoing mastectomy or lumpectomy.
Treatment (abemaciclib, radiation therapy, surgery)EXPERIMENTALPrior to surgery, patients receive abemaciclib orally PO BID on days 1-28. Treatment repeats every 28 days for up to 3 cycles in the absence of disease progression or unacceptable toxicity. Patients undergo radiation therapy over 28 fractions starting on cycle 1 day 15 in the absence of disease progression or unacceptable toxicity. After completion of radiation therapy, patients may undergo surgery. Patients also undergo CT or MRI during screening and on study.
Part A: Abemaciclib, 177Lu-PSMA-617EXPERIMENTALPatients receive abemaciclib lead-in on days 1-14 and lutetium Lu 177 vipivotide tetraxetan IV over 30 minutes on day 15. Treatment repeats every 6 weeks for up to 4 cycles in the absence of disease progression or unacceptable toxicity.
Part B: Recommended Phase 2 dose of Abemaciclib, 177Lu-PSMA-617EXPERIMENTALPatients receive the recommended phase 2 dose of abemaciclib lead-in on days 1-14 and lutetium Lu 177 vipivotide tetraxetan IV over 30 minutes on day 15. Treatment repeats every 6 weeks for up to 4 cycles in the absence of disease progression or unacceptable toxicity.
Part A Cohort A1EXPERIMENTALParticipants received: * Abemaciclib: 70 mg/m², administered orally twice daily (BID). * Irinotecan: 50 mg/m²/day, administered IV on Days 1-5 of each cycle. * Temozolomide: 100 mg/m²/day, administered orally on Days 1-5 of each cycle. Treatment continued until progressive disease, a discontinuation criterion, or unacceptable toxicity. Each cycle lasted 21 days.
Part A Cohort A-1EXPERIMENTALParticipants received: * Abemaciclib: 55 mg/m², administered orally BID. * Irinotecan: 50 mg/m²/day, administered IV on Days 1-5 of each cycle. * Temozolomide: 100 mg/m²/day, administered orally on Days 1-5 of each cycle. Treatment continued until progressive disease, a discontinuation criterion, or unacceptable toxicity. Each cycle lasted 21 days.
Part B Cohort B1EXPERIMENTALParticipants received: * Abemaciclib: 70 mg/m², administered orally BID. * Temozolomide: 100 mg/m²/day, administered orally on Days 1-5 of each cycle. Treatment continued until progressive disease, a discontinuation criterion, or unacceptable toxicity. Each cycle lasted 21 days.
Part B Cohort B2EXPERIMENTALParticipants received: * Abemaciclib: 90 mg/m², administered orally BID. * Temozolomide: 100 mg/m²/day, administered orally on Days 1-5 of each cycle. Treatment continued until progressive disease, a discontinuation criterion, or unacceptable toxicity. Each cycle lasted 21 days.
Part B Cohort B3EXPERIMENTALParticipants received: * Abemaciclib: 115 mg/m², administered orally BID. * Temozolomide: 100 mg/m²/day, administered orally on Days 1-5 of each cycle. Treatment continued until progressive disease, a discontinuation criterion, or unacceptable toxicity. Each cycle lasted 21 days.
Part B Cohort B5EXPERIMENTALParticipants received: * Abemaciclib: 115 mg/m², administered orally BID. * Temozolomide: 150 mg/m²/day, administered orally on Days 1-5 of each cycle. Treatment continued until progressive disease, a discontinuation criterion, or unacceptable toxicity. Each cycle lasted 21 days.
Part C Cohort C1EXPERIMENTALParticipants received: * Abemaciclib: 55 mg/m², administered orally BID. * Irinotecan: 50 mg/m²/day, administered IV on Days 1-5 of each cycle. * Temozolomide: 100 mg/m²/day, administered orally on Days 1-5 of each cycle. * Dinutuximab: 17.5mg/m²/day, administered IV on Days 2-5 of each cycle. * Granulocyte-macrophage colony-stimulating factor (GM-CSF): 250 μg/m²/day, administered subcutaneously (SC) on Days 6-12 of each cycle. Treatment continued until progressive disease, a discontinuation criterion, or unacceptable toxicity. Each cycle lasted 21 days.
LY3819253EXPERIMENTALParticipants received single subcutaneous (SC) doses of 150 milligram (mg), 350 mg or 700 mg LY3819253.
Abemaciclib + Abiraterone Acetate + PrednisoloneEXPERIMENTALAbemaciclib, abiraterone acetate and prednisolone given orally.
Abemaciclib Dose Level 1EXPERIMENTALAbemaciclib 150 milligram (mg) administered every 12 hours, orally, cycle 1 and then in cycle 2. Participants may continue to receive treatment until discontinuation criteria are met. One cycle is defined as 28 days. (Cycle 1: 32 days), with modifications during Cycle 1 to enable pharmacokinetic (PK) sampling following a single dose and repeated doses.
Abemaciclib Dose Level 2EXPERIMENTALAbemaciclib 200 mg administered every 12 hours, orally, cycle 1 and then in cycle 2. Participants may continue to receive treatment until discontinuation criteria are met. One cycle is defined as 28 days. (Cycle 1: 32 days), with modifications during Cycle 1 to enable PK sampling following a single dose and repeated doses.
NSCLC KRAS mt, PD-L1+EXPERIMENTALAbemaciclib given orally every 12 hours (Q12H) on days 1 to 21 of each 21 day cycle in combination with pembrolizumab given intravenously (IV) on day 1 of each 21 day cycle. Participants may continue to receive treatment until discontinuation criteria are met.
NSCLC SquamousEXPERIMENTALAbemaciclib given orally Q12H on days 1 to 21 of each 21 day cycle in combination with pembrolizumab given IV on day 1 of each 21 day cycle. Participants may continue to receive treatment until discontinuation criteria are met.
HR+, HER2- Metastatic Breast CancerEXPERIMENTALAbemaciclib given orally Q12H on days 1 to 21 of each 21 day cycle in combination with pembrolizumab given IV on day 1 of each 21 day cycle. Participants may continue to receive treatment until discontinuation criteria are met.
HR+, HER2- Locally Advanced or Metastatic Breast CancerEXPERIMENTALAbemaciclib given orally Q12H on days 1 to 21 of each 21 day cycle in combination with pembrolizumab given IV on day 1 of each 21 day cycle and anastrozole given orally Q24H on days 1 to 21 of each 21 day cycle. Participants may continue to receive treatment until discontinuation criteria are met.
Placebo + MetforminPLACEBO_COMPARATORSingle dose of placebo administered orally followed by a single dose of metformin administered orally in one of four study periods.
Abemaciclib + MetforminEXPERIMENTALSingle dose of abemaciclib administered orally followed by a single dose of metformin administered orally in one of four study periods.
Placebo + IohexolPLACEBO_COMPARATORSingle dose of placebo administered orally followed by a single dose of iohexol administered intravenously (IV) in one of four study periods.
Abemaciclib + IohexolEXPERIMENTALSingle dose of abemaciclib administered orally followed by a single dose of iohexol administered intravenously (IV) in one of four study periods.
Abemaciclib Part AEXPERIMENTALReference formulation (R) = 3 x 50 mg abemaciclib capsules, Test formulation (T150) = 150 mg abemaciclib tablet administered orally on Day 1 in each of 2 periods.
Abemaciclib Part BEXPERIMENTALR = 3 x 50 mg abemaciclib capsules, T150 = 150 mg abemaciclib tablet, Test Formulation 50 (T50) = 3 x 50 mg abemaciclib tablets administered orally on Day 1 in each of 3 periods.
Abemaciclib Part CEXPERIMENTALT150 Fed and T150 Fasted = 150 mg abemaciclib tablet with a high-fat meal (T150 Fed) and then without a high-fat meal (T150 Fasted) on Day 1 in each of 2 periods administered orally.
LoperamideACTIVE_COMPARATORCohort 2, only. 8 mg Loperamide given orally once in 1 of 4 study periods.
Loperamide + AbemaciclibEXPERIMENTALCohort 2, only. 8 mg Loperamide co-administered with abemaciclib given orally once in up to 1 of 4 study periods.
Loperamide + PlaceboACTIVE_COMPARATORCohort 2, only. 8 mg Loperamide co-administered with placebo given orally once in up to 1 of 4 study periods.
Abemaciclib High Fat MealEXPERIMENTALAbemaciclib capsules administered once orally in the fed state.
Abemaciclib FastedEXPERIMENTALAbemaciclib capsules administered once orally in the fasted state.
Abemaciclib: Normal Hepatic FunctionEXPERIMENTALSingle dose of Abemaciclib administered orally on Day 1 to participants with normal hepatic function.
Abemaciclib: Mild Hepatic ImpairmentEXPERIMENTALSingle dose of Abemaciclib administered orally on Day 1 to participants with mild hepatic impairment.
Abemaciclib: Moderate Hepatic ImpairmentEXPERIMENTALSingle dose of Abemaciclib administered orally on Day 1 to participants with moderate hepatic impairment.
Abemaciclib: Severe Hepatic ImpairmentEXPERIMENTALSingle dose of Abemaciclib administered orally on Day 1 to participants with severe hepatic impairment.
Abemaciclib Alone Period 1EXPERIMENTAL50 mg single oral dose of Abemaciclib was administered in Period 1 Day 1.
Abemaciclib + Clarithromycin Period 2EXPERIMENTALClarithromycin 500 milligram (mg) orally twice daily for 12 days. Single oral dose of Abemaciclib 50 mg on Period 2 Day 5. Clarithromycin dosing continued for 7 days following the single dose of Abemaciclib.
Abemaciclib Safety ExtensionEXPERIMENTALAfter completing Period 2, eligible participants continued to receive 200 mg Abemaciclib every 12 hours (Q12H) on a 28-day cycle in a safety-extension phase until discontinuation criteria were met.
Abemaciclib + PemetrexedEXPERIMENTAL150 milligram (mg) or 200 mg abemaciclib given orally every 12 hours on Days 1 through 21 of a 21-day cycle in combination with 500 milligrams/square meter (mg/m\^2) pemetrexed given intravenously (IV) over approximately 10 minutes on Day 1 of a 21-day cycle. Participants may continue to receive treatment until discontinuation criteria are met.
Abemaciclib + GemcitabineEXPERIMENTAL150 mg or 200 mg abemaciclib given orally every 12 hours on Days 1 through 21 of a 21-day cycle in combination with 1250 milligram/square meter (mg/m\^2) gemcitabine given intravenously over approximately 30 minutes on Days 1 and 8 of a 21-day cycle. Participants may continue to receive treatment until discontinuation criteria are met.
Abemaciclib + RamucirumabEXPERIMENTAL150 mg or 200 mg abemaciclib given orally every 12 hours on Days 1 through 21 of a 21-day cycle in combination with 10 milligram/kilogram (mg/kg) ramucirumab given intravenously over approximately 60 minutes on Day 1 or 8 to 10 milligram/kilogram (mg/kg) ramucirumab given intravenously over approximately 60 minutes on Days 1 and 8 of a 21-day cycle. Participants may continue to receive treatment until discontinuation criteria are met.
Abemaciclib + PembrolizumabEXPERIMENTAL100 mg or 150 mg abemaciclib given orally every 12 hours on Days 1 through 21 of a 21-day cycle in combination with 200 mg pembrolizumab given intravenously over approximately 30 minutes on day 1 of a 21 day cycle. Participants may continue to receive treatment until discontinuation criteria are met.
Arm 1EXPERIMENTAL400 mg of LY3214996 QD for 6 doses and 100 mg of Abemaciclib BID for 11 doses over 5.5 days prior to surgical resection. On Day 6, participants will receive Abemaciclib + LY3214996 dose 7 to 9 hours prior to craniotomy for tumor resection.
Interventions
NameTypeDescription
AbemaciclibDRUGAdministered orally.
AbirateroneDRUGAdministered orally.
Prednisone or PrednisoloneDRUGAdministered orally.
Placebo for AbemaciclibDRUGAdministered orally.
FulvestrantDRUGAdministered IM.
PlaceboDRUGAdministered orally.
Standard Adjuvant Endocrine TherapyDRUGAdministered according to label instructions.
AnastrozoleDRUGAdministered orally
LetrozoleDRUGAdministered orally
ErlotinibDRUGAdministered orally
BiopsyPROCEDUREUndergo tumor biopsy
Bone ScanPROCEDUREUndergo bone scan
CarboplatinDRUGGiven IV
EchocardiographyPROCEDUREUndergo echocardiography
ExemestaneDRUGGiven PO
GefitinibDRUGGiven PO
GemcitabineDRUGGiven IV
Multigated Acquisition ScanPROCEDUREUndergo MUGA
OlaparibDRUGGiven PO
OsimertinibDRUGGiven PO
PaclitaxelDRUGGiven IV
Pegylated Liposomal Doxorubicin HydrochlorideDRUGGiven IV
PemetrexedDRUGGiven IV
Survey AdministrationOTHERAncillary studies
TamoxifenDRUGGiven PO
TemozolomideDRUGGiven PO
Biospecimen CollectionPROCEDUREBiological Sample Collection, Biological Sample Collection, Biospecimen Collected, Biospecimen Collection, Specimen Collection
PembrolizumabDRUGHumanized immunoglobulin G4 monoclonal antibody, 4mL (milliliter) single-dose vial, via intravenous (into the vein) infusion per institutional standard of care.
BicalutamideDRUG150 mg tablet orally once daily
LHRH AgonistDRUGLuteinizing hormone-releasing hormone agonist), taken orally per institutional standard of care
IrinotecanDRUGIV
AtezolizumabDRUGIntravenously Day 1 of 21 day cycle
Abiraterone acetateDRUGAdministered orally.
PrednisoneDRUGAdministered orally.
SurgeryPROCEDURESurgery
LY3023414DRUGAdministered orally
CapecitabineDRUGAdministered orally
Prophylactic LoperamideDRUGAdministered orally
TrastuzumabDRUGAdministered IV
Standard of Care Single Agent ChemotherapyDRUGStandard-of-care single-agent chemotherapy of physician's choice administered according to product label
DocetaxelDRUGAdministered IV
LoperamideDRUGAdministered orally
Niraparib Tosylate MonohydrateDRUGGiven PO
Computed TomographyPROCEDUREUndergo CT
Magnetic Resonance ImagingPROCEDUREUndergo MRI
Radiation TherapyRADIATIONUndergo radiation therapy
Therapeutic Surgical ProcedurePROCEDUREUndergo surgery
Lutetium Lu 177-PSMA-617DRUGGiven IV
DinutuximabDRUGAdministered IV
GM-CSFDRUGAdministered SC
LY3819253DRUGAdministered SC.
PrednisoloneDRUGAdministered orally
MetforminDRUGAdministered orally
IohexolDRUGAdministered intravenously (IV)
Abemaciclib Capsules (Reference Formulation)DRUGAdministered orally
Abemaciclib Tablet (Test Formulation)DRUGAdministered orally
ClarithromycinDRUGAdministered orally
RamucirumabDRUGAdministered IV
LY3214996DRUG400 mg of LY3214996 daily for 6 doses over 5.5 days prior to surgical resection. Participants with tumors demonstrating PK-response in Phase 0 will continue treatment with recommended Phase 2 dose (RP2D) continuously in 21d cycles after surgery.
Unlock Study Design Details
Eligibility Criteria
Age Range18 Years to N/A
SexMALE
Healthy VolunteersNo
Study Sites266

Inclusion Criteria: * Adenocarcinoma of the prostate (as the predominant histology) * High-risk metastatic hormone-sensitive prostate cancer. High risk is defined as: * Greater than or equal to (≥)4 bone metastases by bone scan and/or * ≥1 visceral metastases by computed tomography or magnetic...

Countries:United StatesArgentinaAustraliaBelgiumBrazilCanadaChinaCzechiaFranceGermanyGreeceHungaryIsraelItalyJapanMexicoNetherlandsPolandRomaniaSouth KoreaSpainTaiwanTurkey (Türkiye)United KingdomDenmarkSwedenAustriaFinlandHong KongIndiaNew ZealandPortugalPuerto RicoRussiaSaudi ArabiaSingaporeSouth AfricaUkraineSlovakiaSwitzerland
Unlock Eligibility Criteria
Competitive Landscape -Non-Small Cell Lung Cancer 395 trials (matched to "Non Small Cell Lung Cancer")
Recent Changes (Last 90 Days)
LOWJul 17, 2026NCT06413706primaryCompletionDate: changed
LOWJul 17, 2026NCT06413706primaryCompletionDate: changed
LOWJul 2, 2026NCT06001762enrollmentType: changed
LOWJul 2, 2026NCT05288166lastUpdatePostDate: changed
LOWJul 2, 2026NCT06001762enrollmentType: changed
LOWJul 2, 2026NCT05288166lastUpdatePostDate: changed
LOWJul 2, 2026NCT06001762enrollmentType: changed
LOWJul 2, 2026NCT05288166lastUpdatePostDate: changed
LOWJul 2, 2026NCT05288166lastUpdatePostDate: changed
LOWJun 11, 2026NCT06025747lastUpdatePostDate: changed
LOWJun 11, 2026NCT06025747lastUpdatePostDate: changed
LOWJun 4, 2026NCT06025747lastUpdatePostDate: changed
LOWJun 4, 2026NCT06025747lastUpdatePostDate: changed
LOWJun 4, 2026NCT06025747lastUpdatePostDate: changed
LOWJun 4, 2026NCT06025747lastUpdatePostDate: changed
LOWMay 26, 2026NCT06365788primaryCompletionDate: changed
LOWMay 26, 2026NCT06025747primaryCompletionDate: changed
MEDIUMMay 26, 2026NCT03310879primaryCompletionDate: changed
LOWMay 26, 2026NCT05872204primaryCompletionDate: changed
LOWMay 26, 2026NCT05940493primaryCompletionDate: changed